 |
Echometrix is a Madison-based developer of proprietary ultrasound technology, licensed from WARF, which offers a new quantitative approach to the functional analysis of musculoskeletal injuries. Instead of diagnostic images, the company's products map mechanical properties and behavior of a target tissue. Echometrix will improve musculoskeletal injury diagnostics, while helping to address accelerating costs in musculoskeletal imaging. Early studies demonstrate improvements in injury assessment when compared with traditional ultrasound. The company is well-positioned to address opportunities at the intersection of three growing markets: portable ultrasound, musculoskeletal imaging and orthopedics. For more information, please visit www.echo-metrix.com.
 |
NovaScan, LLC is located at the Cozzens-Cudahy Research Center in Milwaukee and has developed patented technology that electrically images objects. While there are a number of potential applications for the technology, the Company's initial focus is on identifying different tissue types to improve cancer detection. Tissues exhibit electrical behavior that varies by tissue type and disease condition and because of the unique electrical properties of each tissue, it is possible to measure and distinguish diseased from normal tissue. The Company has developed prototype units and has completed preliminary clinical feasibility studies.
 |
Ratio, Inc. is a medical device company developing a technology platform that will enable low-cost, advanced functionality, drug delivery products. Ratio's first product is a one-time-use, disposable pump that adheres to the skin and can deliver a drug painlessly. Currently, three US patents are filed around the core technology aimed at broadly protecting critical components of device operation and proprietary microneedle arrays. Ratio is located in Madison, Wisconsin.
 |
TomoTherapy Incorporated has developed the Hi?Art treatment system, which combines CT imaging and two flexible radiation delivery modes, TomoHelical and TomoDirect, for highly-precise cancer treatments that help limit radiation exposure to surrounding healthy tissue. The Hi?Art treatment system is the only device developed from the ground up for image-guided, intensity-modulated radiation therapy, and allows a consistent planning and treatment process to be applied to a wide range of cancer cases, with confidence in the results. The technology is used to serve cancer cancer patients on more than 225 systems installed around the world.
 |
Wicab, Inc. is focused on the research, development and commercialization of BrainPort® devices, based on a proprietary technology that provides substitute sensory information to the brain via the tongue. Sensory substitution is based on the premise that the input sensors for the human senses can be augmented or substituted by alternate sensors. For example, the BrainPort balance device uses an accelerometer to provide accurate positional information to subjects with balance disorders. The BrainPort vision device uses a digital camera to provide visual images to blind or vision impaired subjects. While there are numerous potential applications for this technology, Wicab is initially focused on the development of the BrainPort balance device for treatment of balance disorders, and the development of the technology for vision and military applications under government sponsored research.
